Xinlitai (002294.SZ): SAL0139 drug clinical trial application accepted

Zhicheng Finance and Economics APP news, Xintai (002294.SZ) announced that the company has received the acceptance notice issued by the National Medical Products Administration. The company's independently developed innovative small molecule drug SAL0139 tablet (project code: SAL0139) has had its clinical trial application accepted. The announcement shows that SAL0139 is a small molecule drug with independent intellectual property rights owned by the company, and the application submitted this time is for the clinical trial of SAL0139 for the treatment of hyperlipidemia.